Vila Petroff MG, Egan JM, Wang X, Sollott SJ: Glucagon- like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes
GI effects are the primary concern, primarily nausea, vomiting, diarrhea, and constipation
Directly, semaglutide has not been shown to harm kidneys and cardiovascular outcome data suggests potential kidney-protective effects in patients with type 2 diabetes.[11] Indirectly, GI side effects that cause dehydration can strain renal function in patients with pre-existing impairment
You get protein, fiber, and wholesome carbohydrates all in a single bowl
[2] Dulaglutide (Trulicity), another once-weekly injectable GLP-1 agonist, demonstrates a somewhat more favourable gastrointestinal tolerability profile in some studies, with nausea reported in approximately 8-12% of patients at lower doses, though rates increase with higher doses (3
Sn phm hin cha c nhiu nghin cu trn ph n c thai hoc cho con b